hmi-115
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05101317)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prolactin receptorANTAGONIST
PRLR
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06118866 | Phase 2 | Sep 11, 2023 | — |
| NCT05324293 | Phase 1 | Apr 30, 2022 | — |
| NCT05101317 | Phase 2 | Nov 30, 2021 | Hope Medicine (Nanjing) Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hope Medicine (Nanjing) Co., Ltd | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1